Free Trial

Brainstorm Cell Therapeutics Q1 2023 Earnings Report

Brainstorm Cell Therapeutics logo
$1.65 +0.06 (+3.77%)
As of 03:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Brainstorm Cell Therapeutics EPS Results

Actual EPS
-$2.10
Consensus EPS
-$2.40
Beat/Miss
Beat by +$0.30
One Year Ago EPS
N/A

Brainstorm Cell Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Brainstorm Cell Therapeutics Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Remove Ads

Brainstorm Cell Therapeutics Earnings Headlines

A market crash is coming—here’s when
The stock market cycle I've used to identify the most likely day of the next market crash is the exact same indicator that helped me call the bear market of 2018... the bull market in 2020... the bear market in 2022... the roaring bull markets in 2023 and 2024... and more. I'm convinced it has helped me identify the next big crash too. We are at an important juncture in the markets. Knowing what to do in the months to come is critical.
BrainStorm Issues 2024 Letter to Shareholders
See More Brainstorm Cell Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Brainstorm Cell Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Brainstorm Cell Therapeutics and other key companies, straight to your email.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics (NASDAQ:BCLI), a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

View Brainstorm Cell Therapeutics Profile

More Earnings Resources from MarketBeat